CVS Health Corp

CVS Health Corp (CVS) Stock Analysis

$92.360

-0.222 (-0.24%)At close

Loading chart…
High
93.345
Open
93.240
VWAP
92.59
Volume
6.98M
Mkt Cap
73.26B
Low
92.050
Amount
646.36M
EV/EBITDA, TTM
8.68

CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.

cvshealth.com

AI analysis of CVS Health Corp (CVS)

Buy

CVS Health Corp is a good buy right now, trading at $92.36 with a forward P/E of 10.67, indicating it is undervalued compared to its earnings potential. The stock has shown a strong 5-day change of +7.20%, reflecting positive momentum. However, the main risk is the recent downgrade in earnings guidance, which could impact future performance, as indicated by the EPS guidance revision to $6.53-$6.75.

Valuation Metrics

The current forward P/E ratio for CVS Health Corp (CVS) is 10.67, compared to its 5-year average forward P/E of 10.50.

Forward P/E

Fair
5Y Average P/E
10.50
Current P/E
10.67
Overvalued
12.11
Undervalued
8.89

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.29
Current EV/EBITDA
8.68
Overvalued
14.75
Undervalued
5.83

Forward P/S

Fair
5Y Average P/S
0.28
Current P/S
0.28
Overvalued
0.36
Undervalued
0.20

Alphio AI Price Scenarios for CVS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CVS

$66.08

Scenario price

B

Base

Base · 50%CVS

$55.76

Scenario price

B

Bear

Bear · 25%CVS

$44.79

Scenario price

Whales holding CVS

T

Turtle Creek Management, LLC

+ HoldingCVS

+19.26%

3M Return

G

GQG Partners, LLC

+ HoldingCVS

+9.34%

3M Return

H

Hotchkis and Wiley Capital Management, LLC

+ HoldingCVS

+9.19%

3M Return

N

Nan Shan Life Insurance Co., Ltd.

+ HoldingCVS

+7.50%

3M Return

P

Pzena Investment Management, Inc.

+ HoldingCVS

+6.58%

3M Return

E

Epoch Investment Partners, Inc.

+ HoldingCVS

+5.66%

3M Return

CVS FAQ — answered by Alphio AI

CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. It operates in the Healthcare sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

CVS Health Corp is a good buy right now, trading at $92.36 with a forward P/E of 10.67, indicating it is undervalued compared to its earnings potential. The stock has shown a strong 5-day change of +7.20%, reflecting positive momentum. However, the main risk is the recent downgrade in earnings guidance, which could impact future performance, as indicated by the EPS guidance revision to $6.53-$6.75.

Community

More ↗
0xSkewfalcon10/5/2026

PeloSwing Weekly Watchlist 👀 $CVS $PEP If you found this watchlist useful, make sure to turn notifications on for more! You don’t want to miss our posts throughout the day!🔔 Let’s have an amazing week! 💰

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading